LeMaitre Vascular, Inc. (NASDAQ: LMAT) Stock Competitors & Peer Comparison
See LMAT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LMAT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LMAT | $95.59 | -1.95% | 2.2B | 37.05 | $2.58 | +0.94% |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
LMAT vs BDX Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas BDX's P/E ratio is 11.62. In terms of profitability, LMAT's ROE is +0.16%, compared to BDX's ROE of +0.05%. Regarding short-term risk, LMAT is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
LMAT vs BDXA Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas BDXA's P/E ratio is 45.70. In terms of profitability, LMAT's ROE is +0.16%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, LMAT is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
LMAT vs MDLN Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas MDLN's P/E ratio is 45.06. In terms of profitability, LMAT's ROE is +0.16%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, LMAT is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
LMAT vs WST Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas WST's P/E ratio is 41.19. In terms of profitability, LMAT's ROE is +0.16%, compared to WST's ROE of +0.19%. Regarding short-term risk, LMAT is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
LMAT vs HOLX Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas HOLX's P/E ratio is 31.54. In terms of profitability, LMAT's ROE is +0.16%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, LMAT is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
LMAT vs COO Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas COO's P/E ratio is 15.42. In terms of profitability, LMAT's ROE is +0.16%, compared to COO's ROE of +0.03%. Regarding short-term risk, LMAT is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
LMAT vs BDXB Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas BDXB's P/E ratio is 7.60. In terms of profitability, LMAT's ROE is +0.16%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, LMAT is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
LMAT vs BAX Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas BAX's P/E ratio is 10.77. In terms of profitability, LMAT's ROE is +0.16%, compared to BAX's ROE of -0.16%. Regarding short-term risk, LMAT is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
LMAT vs ATR Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas ATR's P/E ratio is 23.13. In terms of profitability, LMAT's ROE is +0.16%, compared to ATR's ROE of +0.14%. Regarding short-term risk, LMAT is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
LMAT vs AVTR Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas AVTR's P/E ratio is 13.46. In terms of profitability, LMAT's ROE is +0.16%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, LMAT is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
LMAT vs RGEN Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas RGEN's P/E ratio is 73.31. In terms of profitability, LMAT's ROE is +0.16%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, LMAT is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
LMAT vs TFX Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas TFX's P/E ratio is 12.32. In terms of profitability, LMAT's ROE is +0.16%, compared to TFX's ROE of -0.28%. Regarding short-term risk, LMAT is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
LMAT vs BLCO Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas BLCO's P/E ratio is 24.88. In terms of profitability, LMAT's ROE is +0.16%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, LMAT is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
LMAT vs STVN Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas STVN's P/E ratio is 31.81. In terms of profitability, LMAT's ROE is +0.16%, compared to STVN's ROE of +0.10%. Regarding short-term risk, LMAT is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
LMAT vs MMSI Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas MMSI's P/E ratio is 19.01. In terms of profitability, LMAT's ROE is +0.16%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, LMAT is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
LMAT vs ICUI Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas ICUI's P/E ratio is 19.66. In terms of profitability, LMAT's ROE is +0.16%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, LMAT is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
LMAT vs HAE Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas HAE's P/E ratio is 15.86. In terms of profitability, LMAT's ROE is +0.16%, compared to HAE's ROE of +0.11%. Regarding short-term risk, LMAT is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
LMAT vs XRAY Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas XRAY's P/E ratio is 9.04. In terms of profitability, LMAT's ROE is +0.16%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, LMAT is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check XRAY's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
LMAT vs PLSE Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas PLSE's P/E ratio is -27.48. In terms of profitability, LMAT's ROE is +0.16%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, LMAT is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
LMAT vs ATRC Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, LMAT's ROE is +0.16%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, LMAT is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
LMAT vs BLFS Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas BLFS's P/E ratio is -141.85. In terms of profitability, LMAT's ROE is +0.16%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, LMAT is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
LMAT vs AZTA Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas AZTA's P/E ratio is 60.82. In terms of profitability, LMAT's ROE is +0.16%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, LMAT is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
LMAT vs KMTS Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas KMTS's P/E ratio is -8.92. In terms of profitability, LMAT's ROE is +0.16%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, LMAT is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
LMAT vs STAA Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas STAA's P/E ratio is 41.02. In terms of profitability, LMAT's ROE is +0.16%, compared to STAA's ROE of -0.06%. Regarding short-term risk, LMAT is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
LMAT vs QDEL Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas QDEL's P/E ratio is 11.98. In terms of profitability, LMAT's ROE is +0.16%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, LMAT is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
LMAT vs ATRI Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas ATRI's P/E ratio is 64.50. In terms of profitability, LMAT's ROE is +0.16%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, LMAT is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
LMAT vs ANGO Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas ANGO's P/E ratio is -34.85. In terms of profitability, LMAT's ROE is +0.16%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, LMAT is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
LMAT vs NNNN Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas NNNN's P/E ratio is 145.38. In terms of profitability, LMAT's ROE is +0.16%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, LMAT is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
LMAT vs OSUR Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas OSUR's P/E ratio is -4.78. In terms of profitability, LMAT's ROE is +0.16%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, LMAT is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
LMAT vs SMTI Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas SMTI's P/E ratio is -426.00. In terms of profitability, LMAT's ROE is +0.16%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, LMAT is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
LMAT vs UTMD Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas UTMD's P/E ratio is 19.86. In terms of profitability, LMAT's ROE is +0.16%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, LMAT is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
LMAT vs INFU Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas INFU's P/E ratio is 23.97. In terms of profitability, LMAT's ROE is +0.16%, compared to INFU's ROE of +0.14%. Regarding short-term risk, LMAT is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
LMAT vs KRMD Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas KRMD's P/E ratio is -95.75. In terms of profitability, LMAT's ROE is +0.16%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, LMAT is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
LMAT vs PDEX Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas PDEX's P/E ratio is 19.34. In terms of profitability, LMAT's ROE is +0.16%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, LMAT is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
LMAT vs MBOT Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas MBOT's P/E ratio is -6.58. In terms of profitability, LMAT's ROE is +0.16%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, LMAT is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
LMAT vs AKYA Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas AKYA's P/E ratio is -1.34. In terms of profitability, LMAT's ROE is +0.16%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, LMAT is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
LMAT vs STSS Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas STSS's P/E ratio is -0.02. In terms of profitability, LMAT's ROE is +0.16%, compared to STSS's ROE of -1.66%. Regarding short-term risk, LMAT is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
LMAT vs DXR Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas DXR's P/E ratio is 27.33. In terms of profitability, LMAT's ROE is +0.16%, compared to DXR's ROE of +0.22%. Regarding short-term risk, LMAT is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
LMAT vs OMIC Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas OMIC's P/E ratio is -0.58. In terms of profitability, LMAT's ROE is +0.16%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, LMAT is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
LMAT vs IGAP Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas IGAP's P/E ratio is -10.52. In terms of profitability, LMAT's ROE is +0.16%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, LMAT is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
LMAT vs NEPH Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas NEPH's P/E ratio is 50.86. In terms of profitability, LMAT's ROE is +0.16%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, LMAT is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
LMAT vs MLSS Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas MLSS's P/E ratio is -6.50. In terms of profitability, LMAT's ROE is +0.16%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, LMAT is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
LMAT vs POCI Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas POCI's P/E ratio is -6.07. In terms of profitability, LMAT's ROE is +0.16%, compared to POCI's ROE of -0.37%. Regarding short-term risk, LMAT is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
LMAT vs SDC Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas SDC's P/E ratio is -0.03. In terms of profitability, LMAT's ROE is +0.16%, compared to SDC's ROE of -1.96%. Regarding short-term risk, LMAT is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
LMAT vs HBIO Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas HBIO's P/E ratio is -16.81. In terms of profitability, LMAT's ROE is +0.16%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, LMAT is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
LMAT vs IVC Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas IVC's P/E ratio is -0.79. In terms of profitability, LMAT's ROE is +0.16%, compared to IVC's ROE of -0.46%. Regarding short-term risk, LMAT is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
LMAT vs RVP Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas RVP's P/E ratio is -2.06. In terms of profitability, LMAT's ROE is +0.16%, compared to RVP's ROE of -0.08%. Regarding short-term risk, LMAT is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
LMAT vs ZJYL Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, LMAT's ROE is +0.16%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, LMAT is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
LMAT vs FEMY Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas FEMY's P/E ratio is -10.25. In terms of profitability, LMAT's ROE is +0.16%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, LMAT is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
LMAT vs RGNT Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas RGNT's P/E ratio is -0.08. In terms of profitability, LMAT's ROE is +0.16%, compared to RGNT's ROE of N/A. Regarding short-term risk, LMAT is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
LMAT vs NSTG Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas NSTG's P/E ratio is -0.03. In terms of profitability, LMAT's ROE is +0.16%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, LMAT is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
LMAT vs NXGL Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas NXGL's P/E ratio is -1.13. In terms of profitability, LMAT's ROE is +0.16%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, LMAT is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
LMAT vs POAI Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas POAI's P/E ratio is -0.03. In terms of profitability, LMAT's ROE is +0.16%, compared to POAI's ROE of -107.05%. Regarding short-term risk, LMAT is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
LMAT vs LUCY Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas LUCY's P/E ratio is -0.39. In terms of profitability, LMAT's ROE is +0.16%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, LMAT is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
LMAT vs MHUA Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas MHUA's P/E ratio is 0.25. In terms of profitability, LMAT's ROE is +0.16%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, LMAT is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
LMAT vs NXGLW Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, LMAT's ROE is +0.16%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, LMAT is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
LMAT vs GMVD Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas GMVD's P/E ratio is -0.01. In terms of profitability, LMAT's ROE is +0.16%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, LMAT is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
LMAT vs GMVDW Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas GMVDW's P/E ratio is N/A. In terms of profitability, LMAT's ROE is +0.16%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, LMAT is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
LMAT vs AVGR Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas AVGR's P/E ratio is -0.05. In terms of profitability, LMAT's ROE is +0.16%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, LMAT is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
LMAT vs LUCYW Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, LMAT's ROE is +0.16%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, LMAT is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
LMAT vs GCTK Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas GCTK's P/E ratio is -0.01. In terms of profitability, LMAT's ROE is +0.16%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, LMAT is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for LMAT.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
LMAT vs APR Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, APR has a market cap of 0. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas APR's P/E ratio is 22.59. In terms of profitability, LMAT's ROE is +0.16%, compared to APR's ROE of +9.81%. Regarding short-term risk, LMAT is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
LMAT vs IIN Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, IIN has a market cap of 0. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas IIN's P/E ratio is 226.45. In terms of profitability, LMAT's ROE is +0.16%, compared to IIN's ROE of -0.00%. Regarding short-term risk, LMAT is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
LMAT vs ALOG Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas ALOG's P/E ratio is 40.93. In terms of profitability, LMAT's ROE is +0.16%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, LMAT is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
LMAT vs ATRS Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas ATRS's P/E ratio is 14.95. In terms of profitability, LMAT's ROE is +0.16%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, LMAT is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
LMAT vs IVTY Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas IVTY's P/E ratio is -3.80. In terms of profitability, LMAT's ROE is +0.16%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, LMAT is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
LMAT vs HRC Comparison July 2026
LeMaitre Vascular, Inc. (NASDAQ: LMAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LMAT stands at 2.2B. In comparison, HRC has a market cap of 0. Regarding current trading prices, LMAT is priced at $95.59 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LMAT currently has a P/E ratio of 37.05, whereas HRC's P/E ratio is 41.92. In terms of profitability, LMAT's ROE is +0.16%, compared to HRC's ROE of +0.14%. Regarding short-term risk, LMAT is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for LMAT.Check HRC's competition here